Differences in treatment outcome between translational platforms in developing therapies for gastrointestinal cancers. DOI

Katarzyna Wawrzak-Pienkowska,

Tomasz Pienkowski, Anna Tankiewicz‐Kwedlo

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177309 - 177309

Published: Jan. 1, 2025

Language: Английский

Unveiling the orchestration of T-cell dynamics: A comprehensive examination of their crucial role in revolutionizing immunotherapy for pancreatic and colon cancers DOI

Sridevi Mardham,

Soumya Dakshinamurthy

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 199 - 232

Published: Jan. 1, 2025

Language: Английский

Citations

0
Role of T-cells in immunotherapy of pancreatic and colon cancers DOI

Ashni Dudhia,

Mia Rajan,

Keshav Patel

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 233 - 244

Published: Jan. 1, 2025

Language: Английский

Citations

0
Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases DOI Creative Commons
Alejandrina Hernández-López, Alberto Olaya‐Vargas, Juan Carlos Bustamante‐Ogando

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 156 - 156

Published: Jan. 24, 2025

CAR-T cell therapy has shown promising results in treating malignant hematologic diseases. The principle of this is based on the use genetically modified T lymphocytes to express a Chimeric Antigen Receptor (CAR) their membrane that specifically recognizes an antigen predominantly expressed target cells. molecular design CAR, along with advancements techniques and development “omics”, opened possibility discovering new therapeutic targets thereby expanding range diseases treated cells beyond anti-CD19 anti-BCMA for cancer. This review summarizes novel are currently used clinical trials autoimmune other challenging conditions, such as cardiac fibrosis, different infections. Additionally, challenges opportunities discussed access innovative therapy.

Language: Английский

Citations

0
Multiple myeloma and anti-BCMA CAR-T therapy: a literature review DOI Creative Commons
A. P. Faenko, Г. А. Дудина,

C. K. Mabudzade

et al.

MD-Onco, Journal Year: 2025, Volume and Issue: 4(4), P. 53 - 64

Published: Jan. 15, 2025

Significant progress has been made in the treatment of multiple myeloma (MM), leading to improved clinical outcomes. However, despite success traditional methods such as surgery, radiotherapy, and chemotherapy, challenge fully curing patients with relapsed refractory MM remains pressing. A promising therapeutic approach is use chimeric antigen receptor T-cells (CAR-T), which demonstrated efficacy resistant B-cell malignancies actively being studied for MM. Special attention given maturation (BCMA) a potential target CAR-T therapy The objective analyze current state anti-BCMA ММ, covering aspects production, preclinical trials, well examining therapy-related toxicity relapses. Data analysis was conducted using specialized medical databases PubMed, Scopus, Web Science, Frontiers, Google Scholar from 1974 2024. article reviews latest achievements MM, advances production application BCMA CAR T-cells, along key challenges faced by this technology. data obtained confirm significant optimizing T-cell structures improving manufacturing processes, making more accessible use. Although early-phase trials show results, remain, insufficient response some patients. Optimization structure technologies may improve accessibility therapy, it direction future research.

Language: Английский

Citations

0
Differences in treatment outcome between translational platforms in developing therapies for gastrointestinal cancers. DOI

Katarzyna Wawrzak-Pienkowska,

Tomasz Pienkowski, Anna Tankiewicz‐Kwedlo

et al.

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177309 - 177309

Published: Jan. 1, 2025

Language: Английский

Citations

0